H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Krystal Biotech Inc (KRYS) today and set a price target of $32. The company’s shares opened today at $25.10.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $32 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our model currently received the majority of valuation contribution from KB103 for the treatment of DEB patients, with modest contribution from KB105 for ARCI.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -20.9% and a 22.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Krystal Biotech Inc is a Strong Buy with an average price target of $38.67, which is a 54.1% upside from current levels. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $34 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $28.75 and a one-year low of $8.61. Currently, Krystal Biotech Inc has an average volume of 88.61K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KRYS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017and is headquartered in Pittsburgh, PA.